Search

Novo Nordisk A-S (Class B)

Open

319.55 -1.08

Overview

Share price change

24h

Current

Min

316.25

Max

324.7

Key metrics

By Trading Economics

Income

804M

29B

Sales

-7.6B

78B

P/E

Sector Avg

13.098

34.393

EPS

6.53

Dividend yield

3.64

Profit margin

37.182

Employees

77,406

EBITDA

39B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+9.53% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.64%

2.54%

Next Dividend date

19 Aug 2025

Next Ex Dividend date

14 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-639B

1.4T

Previous open

320.63

Previous close

319.55

Novo Nordisk A-S (Class B) Chart

Past performance is not a reliable indicator of future results.

Related News

6 Aug 2025, 06:52 UTC

Earnings

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 Aug 2025, 06:21 UTC

Earnings

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

8 Aug 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 Aug 2025, 11:32 UTC

Earnings

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 Aug 2025, 11:03 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 Aug 2025, 10:41 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 Aug 2025, 20:34 UTC

Earnings

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 Aug 2025, 08:45 UTC

Earnings

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 Aug 2025, 07:19 UTC

Market Talk
Earnings

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 Aug 2025, 05:50 UTC

Earnings

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 Aug 2025, 05:48 UTC

Earnings

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 Aug 2025, 05:46 UTC

Earnings

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 Aug 2025, 05:38 UTC

Earnings

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 Aug 2025, 05:37 UTC

Earnings

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 Aug 2025, 05:36 UTC

Earnings

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 Aug 2025, 05:35 UTC

Earnings

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 Aug 2025, 05:34 UTC

Earnings

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6 Aug 2025, 05:31 UTC

Earnings

Novo Nordisk 2Q Net Pft DKK26.5B

6 Aug 2025, 05:31 UTC

Earnings

Novo Nordisk 2Q Oper Pft DKK33.45B

6 Aug 2025, 05:31 UTC

Earnings

Novo Nordisk 2Q Sales DKK76.86B

5 Aug 2025, 21:58 UTC

Earnings

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 Aug 2025, 17:26 UTC

Earnings
Acquisitions, Mergers, Takeovers

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 Aug 2025, 15:15 UTC

Earnings

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5 Aug 2025, 10:07 UTC

Market Talk

Novo Nordisk's Facing Challenging Times -- Market Talk

1 Aug 2025, 11:10 UTC

Hot Stocks

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

30 Jul 2025, 11:10 UTC

Market Talk
Earnings

Novo Nordisk Suffering From Self-Inflicted Wounds -- Market Talk

30 Jul 2025, 10:57 UTC

Market Talk

Novo Nordisk's New CEO Might Need to Change U.S. Strategy -- Market Talk

30 Jul 2025, 10:48 UTC

Market Talk
Earnings

Novo Nordisk's New CEO Faces Issues With No Easy Fix -- Market Talk

30 Jul 2025, 10:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Stock Markets Beware Summer Scares. What -2-

30 Jul 2025, 10:42 UTC

Earnings
Acquisitions, Mergers, Takeovers

Stock Markets Beware Summer Scares. What Microsoft Must Learn From Novo's $75 Billion Crash. -- Barrons.com

Novo Nordisk A-S (Class B) Forecast

Price Target

By TipRanks

9.53% upside

12 Months Forecast

Average 1,162.73 DKK  9.53%

High 1,550 DKK

Low 720 DKK

Based on 11 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S (Class B) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

7

Buy

2

Hold

2

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.